Trials / Completed
CompletedNCT05267028
Rehabilitation of Facial Emotion Recognition in Alzheimer's Disease
Rehabilitation of Facial Emotion Recognition in Alzheimer's Disease and Study of the Consequences on Gaze Strategy, Behavior Disorders and Family Caregivers' Burden
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 16 (actual)
- Sponsor
- Association de Recherche Bibliographique pour les Neurosciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
EYE-TAR(AD+) is an observational study based on the same design as the princeps EYE-TAR(MA) study, but with a larger number of patients and including an additional evaluation of Facial emotion recognition (based on a more ecological material), in order to reinforce conclusions of the study EYE-TAR(MA) https://doi.org/10.1016/j.npg.2020.08.003. The main objective is to confirm that facial emotion recognition can be improved in AD using the "Training of Affect Recognition program" (TAR). The Secondary Objectives are to: Evaluate the impact of the "Training of Affect Recognition program" (TAR) on oculomotor behavior in a situation of social cognition, on behavioral disorders and on caregiver burden. Confirm that improvement in facial emotion recognition is related to modification of observation strategies. Confirm the link between improved recognition of facial emotions, reduced behavioral disorders and caregiver burden.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | AD-TAR | 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR). |
| OTHER | AD-Cognitive Stimulation | 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops. |
Timeline
- Start date
- 2022-02-10
- Primary completion
- 2023-03-22
- Completion
- 2023-03-22
- First posted
- 2022-03-04
- Last updated
- 2023-03-31
Locations
1 site across 1 country: Monaco
Source: ClinicalTrials.gov record NCT05267028. Inclusion in this directory is not an endorsement.